NASDAQ:SLDB - Solid Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.17
  • Forecasted Upside: 308.30 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.49
▼ -0.11 (-4.23%)

This chart shows the closing price for SLDB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Solid Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLDB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLDB

Analyst Price Target is $10.17
▲ +308.30% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Solid Biosciences in the last 3 months. The average price target is $10.17, with a high forecast of $17.00 and a low forecast of $6.00. The average price target represents a 308.30% upside from the last price of $2.49.

This chart shows the closing price for SLDB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Solid Biosciences. This rating has held steady since May 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/24/2021Chardan CapitalLower Price TargetBuy$20.00 ➝ $17.00High
7/12/2021Piper SandlerInitiated CoverageNeutral$6.00High
7/1/2021Chardan CapitalReiterated RatingBuyHigh
5/27/2021Jefferies Financial GroupInitiated CoverageBuy$7.00High
5/17/2021BarclaysLower Price TargetOverweight$13.00 ➝ $8.00Medium
3/16/2021Chardan CapitalBoost Price TargetBuy$12.50 ➝ $20.00High
3/16/2021Credit Suisse GroupBoost Price TargetNeutral$7.00 ➝ $8.00High
3/16/2021SVB LeerinkUpgradeMarket Perform ➝ Outperform$3.00 ➝ $15.00High
3/14/2021SVB LeerinkReiterated RatingHold$3.00Low
3/9/2021BarclaysInitiated CoverageOverweight$13.00High
1/8/2021Chardan CapitalReiterated RatingBuy$12.50High
1/8/2021Credit Suisse GroupUpgradeUnderperform ➝ Neutral$2.00 ➝ $7.00High
10/1/2020Chardan CapitalBoost Price TargetBuy$5.00 ➝ $12.50High
8/14/2020Chardan CapitalReiterated RatingBuy$5.00Medium
7/27/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$3.00High
5/21/2020NomuraReiterated RatingBuy$6.00Low
5/9/2020Chardan CapitalReiterated RatingBuy$5.00High
5/8/2020NomuraLower Price TargetBuy$10.00 ➝ $6.00Low
3/23/2020Chardan CapitalReiterated RatingBuy$6.75 ➝ $5.00High
12/18/2019Nomura SecuritiesBoost Price TargetBuy$6.00 ➝ $10.00High
11/12/2019Credit Suisse GroupLower Price TargetUnderperform ➝ Hold$6.00 ➝ $2.00High
10/11/2019Evercore ISIInitiated CoverageOutperform$22.00High
8/29/2019CitigroupDowngradeNeutral ➝ Sell$6.00High
8/19/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$8.00 ➝ $15.00High
8/16/2019Chardan CapitalUpgradeNeutral ➝ Buy$7.50 ➝ $10.00High
5/16/2019CitigroupSet Price TargetHold$6.00Low
5/14/2019Chardan CapitalDowngradeBuy ➝ Neutral$15.00 ➝ $7.50High
5/14/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$5.00 ➝ $4.00High
5/14/2019Credit Suisse GroupDowngradeNeutral ➝ Underperform$7.00 ➝ $6.00High
2/8/2019SVB LeerinkDowngradeOutperform ➝ Market PerformLow
2/8/2019CitigroupUpgradeSell ➝ Neutral$8.00Medium
2/7/2019Chardan CapitalReiterated RatingBuy$15.00High
12/10/2018BTIG ResearchInitiated CoverageNeutralLow
12/3/2018CitigroupBoost Price TargetHold ➝ Sell$25.00 ➝ $31.00High
11/6/2018CitigroupInitiated CoverageSell$25.00High
9/6/2018Credit Suisse GroupInitiated CoverageNeutral ➝ Neutral$38.00High
6/25/2018Nomura SecuritiesBoost Price TargetBuy$37.00 ➝ $57.00High
6/24/2018Chardan CapitalReiterated RatingBuy$60.00Low
6/20/2018SVB LeerinkBoost Price TargetOutperform$28.00 ➝ $50.00High
5/10/2018Chardan CapitalReiterated RatingBuy$37.50Low
5/10/2018SVB LeerinkBoost Price TargetOutperform$14.00 ➝ $28.00Low
4/2/2018SVB LeerinkLower Price TargetOutperform ➝ Hold$36.00 ➝ $14.00Medium
3/19/2018Nomura SecuritiesLower Price TargetBuy ➝ Buy$52.00 ➝ $37.00Low
3/15/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$28.00High
2/21/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$40.00High
2/20/2018Nomura SecuritiesInitiated CoverageBuy ➝ Buy$52.00Medium
2/20/2018Nomura InstinetInitiated CoverageBuy$52.00High
2/20/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$36.00High
2/20/2018JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$28.00High
2/20/2018The Goldman Sachs GroupInitiated CoverageNeutral$31.00High
(Data available from 9/28/2016 forward)

News Sentiment Rating

0.74 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 6 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/28/2021

Current Sentiment

  • 6 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Solid Biosciences logo
Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy (DMD). It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $2.49
Low: $2.47
High: $2.57

50 Day Range

MA: $2.74
Low: $2.42
High: $3.20

52 Week Range

Now: $2.49
Low: $2.01
High: $11.58

Volume

23,134 shs

Average Volume

1,213,231 shs

Market Capitalization

$274.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Solid Biosciences?

The following sell-side analysts have issued research reports on Solid Biosciences in the last twelve months: Barclays PLC, Chardan Capital, Credit Suisse Group AG, Jefferies Financial Group Inc., Piper Sandler, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for SLDB.

What is the current price target for Solid Biosciences?

6 Wall Street analysts have set twelve-month price targets for Solid Biosciences in the last year. Their average twelve-month price target is $10.17, suggesting a possible upside of 291.0%. Chardan Capital has the highest price target set, predicting SLDB will reach $17.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $6.00 for Solid Biosciences in the next year.
View the latest price targets for SLDB.

What is the current consensus analyst rating for Solid Biosciences?

Solid Biosciences currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SLDB will outperform the market and that investors should add to their positions of Solid Biosciences.
View the latest ratings for SLDB.

What other companies compete with Solid Biosciences?

How do I contact Solid Biosciences' investor relations team?

Solid Biosciences' physical mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 337-4680. The official website for Solid Biosciences is www.solidbio.com.